Home » Newsletters » BioWorld

BioWorld

Oct. 3, 1997

View Archived Issues

FDA Says Sonus Can Skip Advisory Panel Review

Other News To Note

NIH Project To Investigate Relation Of Gene-Environment Interactions To Diseases

Cypros Plans Phase III Trials Of Drugs For Prevention Of Ischemia-Related Damage

Customized Antitumor Vaccine Immunizes Mice, People Against Cancers

Inspire Raises $13M To Fund Respiratory Drug Program

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.